A combinatorial approach might be less therapeutically valuable if AML patient samples could be grouped into discrete groups of BCL-2 over-expressers and MCL-1 over-expressers, thereby stratifying this population into subsets potentially responsive to each drug as a single agent. This evidence concerns the gene MCL1 and acute myeloid leukemia.